Therus Corporation develops manufactures and markets therapeutic ultrasound products that provide cost effective, less-invasive and noninvasive, surgical treatment of benign and malignant disease, including management of bleeding. The company was formed to exploit clinical applications of High Intensity Focused Ultrasound. The management team is evaluating the best commercial applications, including acoustic hemostasis, arterial sealing and tumor ablation, with the long-term vision of non-invasive, image-guided surgery. Therus is developing the TheraSeal System, an ultrasound-based device that noninvasively targets and delivers to the puncture site ultrasound energy that induces sealing in seconds. The approach is independent of the puncture size and the patient's coagulation status because the mechanism of sealing is not dependent on clotting. The device is noninvasive, and no foreign materials are introduced into the catheter track, thereby reducing the risk of complication.
